All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

delgocitinib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
Janus kinase inhibitors, antineoplastics	5426	1263774-59-9

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: delgocitinib JTE-052 JTE-052A LEO 124249 LEO 124249A LP0133 corectim

Delgocitinib, a janus kinase (JAK) inhibitor, is being approved for the treatment of inflammatory skin conditions. Delgocitinib inhibited the activation of inflammatory cells, such as T cells, B cells, monocytes and mast cells, in vitro and inhibited Th1-, Th2- and Th17-type cytokine production from both T cells and non-T cells. Molecular weight: 310.36 Formula: C16H18N6O CLOGP: 1 LIPINSKI: 0 HAC: 7 HDO: 1 TPSA: 88.91 ALOGS: -2.75 ROTB: 2 Status: ONP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	AAK1,ACVR2A,ACVR2B,ACVRL1,AKT1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BLK,BRAF,CAMK2B,CAMK2D,CDK1,CDK5,CDK9,CHEK1,CLK2,CLK4,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,FGFR1,FLT3,GRK1,GRK2,GRK3,GSK3B,IGF1R,IKBKB,IRAK1,ITK,JAK1,JAK2,JAK3,KIT,LCK,LRRK2,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K2,MAP3K21,MAP4K1,MAP4K2,MAP4K3,MAP4K5,MAPK1,MAPK10,MAPK3,MAPK7,MAPK9,MARK4,MELK,MET,MINK1,NTRK1,NUAK1,PAK4,PDK1,PDK2,PIK3CD,PRKAA1,PRKAA2,PRKACA,PRKCD,PRKDC,PRKG1,ROCK1,ROCK2,RPS6KA1,SGK1,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1,ULK2	88
kinase-selectivity-class	AAK1,ACVR2B,AKT1,AURKA,AURKB,AXL,CAMK2B,CAMK2D,CDK9,CHEK1,CLK2,CLK4,CSF1R,DYRK1B,EGFR,FGFR1,FLT3,HASPIN,IRAK1,JAK1,JAK2,JAK3,LRRK2,MAP3K10,MAP3K11,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MARK3,MARK4,MELK,NTRK1,NUAK1,PDK1,PRKAA1,PRKAA2,PRKACA,PRKCD,ROCK1,ROCK2,SIK2,SIK3,STK33,SYK,ULK1	47
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Jan. 23, 2020	PMDA	Japan Tobacco

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product use in unapproved indication	102.34	94.69	29	64	447348	110141858

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D11AH11	DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Agents for dermatitis, excluding corticosteroids
MeSH PA	D000075242	Janus Kinase Inhibitors
MeSH PA	D003879	Dermatologic Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D047428	Protein Kinase Inhibitors
FDA MoA	N0000190857	Janus Kinase Inhibitors
FDA EPC	N0000190858	Janus Kinase Inhibitor
CHEBI has role	CHEBI:35472	anti-inflammatory drug
CHEBI has role	CHEBI:50177	dermatologic drug
CHEBI has role	CHEBI:50748	antipsoriatic
CHEBI has role	CHEBI:59010	antiseborrheic
CHEBI has role	CHEBI:76617	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor

Related Drugs by ATC class:

D11AH Agents for dermatitis, excluding corticosteroids 11 drugs

abrocitinibalitretinoincrisaborolecromoglicic aciddupilumablebrikizumabnemolizumabpimecrolimusruxolitinibtacrolimustralokinumab

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Atopic dermatitis	indication	24079001	DOID:3310

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
2%	ANZUPGO	LEO PHARMA AS	N219155	July 23, 2025	RX	CREAM	TOPICAL	8609647	Sept. 19, 2031	METHOD OF INHIBITING JANUS KINASE 2 OR JANUS KINASE 3 TO TREAT MODERATE TO SEVERE CHRONIC HAND ECZEMA (CHE) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO, OR FOR WHOM TOPICAL CORTICOSTEROIDS ARE NOT ADVISABLE

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
2%	ANZUPGO	LEO PHARMA AS	N219155	July 23, 2025	RX	CREAM	TOPICAL	July 23, 2030	NEW CHEMICAL ENTITY

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Tyrosine-protein kinase JAK3	Kinase	P52333	JAK3_HUMAN	INHIBITOR	IC50	7.89		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Tyrosine-protein kinase JAK1	Kinase	P23458	JAK1_HUMAN	INHIBITOR	IC50	8.55		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Tyrosine-protein kinase JAK2	Kinase	O60674	JAK2_HUMAN	INHIBITOR	IC50	8.58		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Non-receptor tyrosine-protein kinase TYK2	Kinase	P29597	TYK2_HUMAN	INHIBITOR	IC50	7.24		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Signal transducer and activator of transcription 3	Transcription factor	P40763	STAT3_HUMAN		IC50	7.75		CHEMBL
Rho-associated protein kinase 2	Kinase	O75116	ROCK2_HUMAN	INHIBITOR	IC50	6.58		SCIENTIFIC LITERATURE
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		IC50	5.24		CHEMBL

External reference:

ID	Source
D11046	KEGG_DRUG
9L0Q8KK220	UNII
C5226741	UMLSCUI
CHEBI:167600	CHEBI
CHEMBL4297507	ChEMBL_ID
50914062	PUBCHEM_CID
DB16133	DRUGBANK_ID
10574	INN_ID
C000621572	MESH_SUPPLEMENTAL_RECORD_UI
9619	IUPHAR_LIGAND_ID
567841000202108	SNOMEDCT_US
4044148	VANDF
FHX	PDB_CHEM_ID
44276	MMSL
019994	NDDF
2721163	RXNORM

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Anzupgo	HUMAN PRESCRIPTION DRUG LABEL	1	50222-280	CREAM	20 mg	TOPICAL	NDA	27 sections